Anticholinergics for Overactive Bladder in Frail and Medically Complex Older People: The Case For
Overactive bladder (OAB) is a common, troublesome condition affecting the lives of many older people. When pharmacotherapy is considered, antimuscarinics remain the mainstay for treatment. Bladder antimuscarinics are effective in the relief of symptoms for OAB and treatment leads to significant improvements in quality of life for those with the condition. However, many older people (> 65 years) with OAB are in later life (> 75 years) and a proportion of these will either be medically complex, with multiple comorbid conditions, or frail. This article discusses the evidence for OAB treatment in the frail or medically complex elderly, outlines where caution should be exercised, giving examples from the recent literature, and advocates for an active approach for this group, who are often left without any treatment.
Compliance with Ethical Standards
Conflicts of interest and funding
Adrian Wagg has received, either personally or for his institution, financial support for research, speaker honoraria or consultancy fees, from Astellas Pharma, Pfizer Corporation and Essity Health and Hygiene AB. No support was connected to this article.
- 3.Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101:1388–95.CrossRefPubMedGoogle Scholar
- 13.National Collaborating Centre for Women’s and Children’s Health (UK). Urinary Incontinence in Women: The Management of Urinary Incontinence in Women. London. Royal College of Obstetricians and Gynaecologists; 2013.Google Scholar
- 24.Wagg A, Diles, D. Four year persistence and drug treatment patterns in overactive bladder: data from Canadian datasets. 68th Annual Meeting of the Canadian Urological Association; 22–25 Jun 2013: Niagra Falls, ON.Google Scholar
- 27.Cheng LI, Durden E, Limone B, et al. Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the United States. J Manag Care Spec Pharm. 2015;21(824–33):33a.Google Scholar
- 31.Oelke M, Murgas S, Schneider T, Heßdörfer E. Influence of propiverine ER 30 mg once daily on cognitive function in elderly female and male patients with overactive bladder: a noninterventional study to assess real life data. Proceedings of the International Continence Society Annual Scientific Meeting, 2013:201.Google Scholar
- 34.Stuhec M. Solifenacin-induced delirium and hallucinations. Gen Hosp Psychiatry. 2013;35(682):e3–4.Google Scholar
- 38.Kay G, Kardiasmenos, K., Crook, T. Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutynin chloride ER on recent memory in older subjects. Proceedings of the 36th meeting of the International Continence Society, 2006;25:P087.Google Scholar
- 40.Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc. 2008;56:862–70.CrossRefPubMedGoogle Scholar
- 44.LaBossiere J, Fernet M, Herschorn S, Carlsson M, Oelke M, Wagg A. Symptom relief from OAB. What an “average” patient might expect: data from a pooled analysis of fesoterodine treated patients. Proceedings of the International Continence Society Annual Scientific Meeting; 28–31 Aug 2018: Philadelphia (PA).Google Scholar